Updating results

70 results for dyspepsia

Sort: Date | Relevance

Bile acid malabsorption: colesevelam (ESUOM22)

Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

Evidence summary Published October 2013

Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

Summary of the evidence on tadalafil for lower urinary tract symptoms secondary to benign prostate hyperplasia..

Evidence summary Published May 2013 Last updated October 2013

Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

Evidence summary Published September 2013

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Gastroparesis in adults: oral erythromycin (ESUOM13)

Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

Evidence summary Published June 2013

Generalised anxiety disorder: quetiapine (ESUOM12)

Summary of the evidence on quetiapine monotherapy for treating generalised anxiety disorder (GAD) to inform local NHS planning and decision-making

Evidence summary Published May 2013

Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

Summary of the evidence on vaginal misoprostol (after oral mifepristone) for induction labour in late intrauterine fetal death (IUFD)..

Evidence summary Published April 2013

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275)

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)

Technology appraisal guidance Published February 2013

Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

Summary of the evidence on glycopyrronium bromide for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published January 2013

Smokeless tobacco: South Asian communities (PH39)

This guideline covers people living in England with ancestral links to Bangladesh, India, Nepal, Pakistan or Sri Lanka who use traditional South Asian varieties of smokeless tobacco. The aim is to help them stop using tobacco that is placed in the mouth or nose (but not burned). It does not include oral snuff products that are sucked.

Public health guideline Published September 2012

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism

Technology appraisal guidance Published July 2012

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published May 2012

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published March 2012

Barrett's oesophagus: ablative therapy (CG106)

This guideline covers endoscopy treatments for people aged 18 and over with Barrett’s oesophagus and high-grade dysplasia or intramucosal cancer. It offers advice on which types of endoscopy treatments should be offered and how these should be used. It aims to improve choice of treatment for adults with Barrett’s oesophagus and improve quality of life and survival for those who cannot have surgery.

Clinical guideline Published August 2010

Infliximab for acute exacerbations of ulcerative colitis (TA163)

Evidence-based recommendations on infliximab (Remicade) for acute exacerbations of ulcerative colitis in adults

Technology appraisal guidance Published December 2008

Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease (IPG222)

Evidence-based recommendations on endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for gastro-oesophageal reflux

Interventional procedures guidance Published June 2007

Catheterless oesophageal pH monitoring (IPG187)

Evidence-based recommendations on catheterless oesophageal pH monitoring (placing small wireless capsule in gullet to check the level of acid)

Interventional procedures guidance Published July 2006

Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B

Technology appraisal guidance Published February 2006